TScan Therapeutics appoints R. Keith Woods to Board of Directors, effective immediately

TScan Therapeutics, Inc.

Woods appointed as Class II director, serving on Audit and Compensation Committees.
Over 30 years life science experience; most recently COO of argenx, leading commercialization.
Received option to purchase 17,500 shares of TCRX common stock, vesting over one year or until 2024 annual meeting.
Board committees: Audit (Woods, Dorton, Gruia, Klencke); Compensation (Woods, Biggar, Dorton, Klencke).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

R. Keith Woods

Class II director

TCRX · TScan Therapeutics, Inc.

Effective: 2023-12-06
Filed: December 7, 2023, 6:59 PM ET

On December 6, 2023, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed R. Keith Woods, to the Board, effective December 6, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

R. Keith Woods was appointed as Class II director at TScan Therapeutics, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

On December 6, 2023, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed R. Keith Woods, to the Board, effective December 6, 2023.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-290309

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.